Wang Yuxuan, Zhen Hongnan, Hu Ke, Yu Lang, Zhang Jie, Luo Chunli, Yu Lihua, Yan Junfang, Zhang Fuquan
Department of Radiation Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Department of Radiation Oncology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.
Clin Transl Radiat Oncol. 2024 Sep 21;49:100867. doi: 10.1016/j.ctro.2024.100867. eCollection 2024 Nov.
This study represents a prospective phase I clinical research to verify the effectiveness and reliability of hydrogel application in Chinese cervical cancer patients.
Eight patients were enrolled in the study. After completing intensity-modulated radiotherapy at 50.4 Gy/28 fractions, a 10 mL injection of hydrogel was administered to each patient through the posterior vaginal fornix under CT-guidance. Image-guided brachytherapy under CT or MRI guidance was given with a target dose of 6 Gy in 5 fractions to the high-risk clinical target volume. Rectal, sigmoid colon, and bladder D2cm3 were recorded for each brachytherapy. MRI scans were performed to measure the distance between the rectum and the cervix or tumor, as well as the spacer gel volume. Patients' QLQ-C30 and QLQ-CX24 scores were recorded to assess treatment outcomes, and all adverse events were documented.
Among the eight patients, the average D2cc was 60.9 ± 3.4 Gy for the rectum, 64.7 ± 6.8 Gy for sigmoid colon and 77.1 ± 7.4 Gy for bladder, respectively. The distance between the cervix and rectum significantly increased after gel injection. None of the eight patients experienced grade 3 or higher acute toxic reactions during brachytherapy. None patient experienced late rectal toxicity. No adverse events definitively associated with the hydrogel were observed. Patients' subjective quality of life scores did not significantly change before and after gel injection. The reduction ro the volume of the hydrogel were observed during the 24 to 36 weeks after injection.
The application of the hydrogel effectively increased the distance between the cervix and rectum in brachytherapy for cervical cancer, limiting the rectal dose without increasing doses to other critical organs. In the short term, no severe adverse events were observed, indicating the safety and reliability of this approach. Further research is warranted to confirm its long-term safety and effectiveness.
本研究是一项前瞻性I期临床研究,旨在验证水凝胶应用于中国宫颈癌患者的有效性和可靠性。
8例患者纳入本研究。在完成50.4 Gy/28次分割的调强放疗后,在CT引导下经阴道后穹窿给每位患者注射10 mL水凝胶。在CT或MRI引导下进行图像引导近距离放疗,高危临床靶体积的靶剂量为6 Gy,分5次给予。每次近距离放疗时记录直肠、乙状结肠和膀胱的D2cm3。进行MRI扫描以测量直肠与宫颈或肿瘤之间的距离以及间隔凝胶体积。记录患者的QLQ-C30和QLQ-CX24评分以评估治疗效果,并记录所有不良事件。
8例患者中,直肠的平均D2cc为60.9±3.4 Gy,乙状结肠为64.7±6.8 Gy,膀胱为77.1±7.4 Gy。注射凝胶后宫颈与直肠之间的距离显著增加。8例患者在近距离放疗期间均未发生3级或更高等级的急性毒性反应。无患者发生晚期直肠毒性。未观察到与水凝胶明确相关的不良事件。注射凝胶前后患者的主观生活质量评分无显著变化。注射后24至36周观察到水凝胶体积减小。
水凝胶的应用在宫颈癌近距离放疗中有效增加了宫颈与直肠之间的距离,限制了直肠剂量,而未增加其他关键器官的剂量。短期内未观察到严重不良事件,表明该方法的安全性和可靠性。有必要进一步研究以证实其长期安全性和有效性。